Brief: Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
29/12/2025 13:35
Dec 29 (Reuters) - Unicycive Therapeutics Inc UNCY.O: UNICYCIVE THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION (NDA) FOR OXYLANTHANUM CARBONATE (OLC) UNICYCIVE THERAPEUTICS INC - NDA RESUBMITTED AFTER VENDOR RESOLVES FDA DEFICIENCIES UNICYCIVE THERAPEUTICS INC - NDA SUBMISSION REVIEW EXPECTED WITHIN 6 MONTHS PER PRESCRIPTION DRUG USER FEE ACT Source text: ID:nGNX45m1Fr Further company coverage: UNCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss